James Palacino Email

Head Biology . Orum Therapeutics

Daejeon, --Select--

Location

LinkedIn

Current Roles

Employees:
44
Revenue:
$3.4M
About
Orum Therapeutics is a private biotech developing next-generation TPD technologies. Orum's novel and proprietary next generation targeted protein degradation (TPD) platform, TPD2 AnDC (Antibody neoDegrader Conjugate), enables tumor-specific targeting for multiple indications. Orum was founded in 2016 and has labs and offices operating out of Daejeon, South Korea, and Cambridge, MA, US.
Orum Therapeutics Address
20 Acorn Park Drive
Daejeon, --Select--
Orum Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.